Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.
about
Structural Insights into High Density Lipoprotein: Old Models and New Facts3-nitrotyrosine modified proteins in atherosclerosisReactive nitrogen species in cellular signalingTyrosine-Nitrated Proteins: Proteomic and Bioanalytical Aspects.Immunochemical Approach for Monitoring of Structural Transition of ApoA-I upon HDL Formation Using Novel Monoclonal AntibodiesHDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of functionMyeloperoxidase-mediated Methionine Oxidation Promotes an Amyloidogenic Outcome for Apolipoprotein A-I.Comparative proteome analysis of abdominal adipose tissues between fat and lean broilers.Reconstituted high-density lipoproteins promote wound repair and blood flow recovery in response to ischemia in aged mice.Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone MiceNitrated apolipoprotein AI/apolipoprotein AI ratio is increased in diabetic patients with coronary artery diseaseA Systematic Investigation of Structure/Function Requirements for the Apolipoprotein A-I/Lecithin Cholesterol Acyltransferase Interaction Loop of High-density Lipoprotein.α-Tocopherol supplementation reduces 5-nitro-γ-tocopherol accumulation by decreasing γ-tocopherol in young adult smokersImproved Incorporation of Noncanonical Amino Acids by an Engineered tRNA(Tyr) Suppressor.Molecular biology of calcific aortic valve disease: towards new pharmacological therapies.High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease.Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies.Biomarkers of plaque instability.Dysfunctional HDL and atherosclerotic cardiovascular disease.Influence of HDL particles on cell-cholesterol efflux under various pathological conditions.ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.Genetic control of apoprotein A-I and atheroprotection: some insights from inbred strains of mice.Copper futures: ceruloplasmin and heart failure.Apolipoprotein A-I and cholesterol efflux: the good, the bad, and the modified.Commercially available gluten-free pastas elevate postprandial glycemia in comparison to conventional wheat pasta in healthy adults: a double-blind randomized crossover trial.Characterization of covalent modifications of HDL apoproteins by endogenous oxidized phospholipids.Chemical biology approaches for studying posttranslational modifications.Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA.Exploring the Predictive Ability of Dysfunctional High-Density Lipoprotein for Adverse Outcomes in Emergency Department Patients with Sepsis: A Preliminary Investigation.Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.Genetic Code Expansion: A Powerful Tool for Understanding the Physiological Consequences of Oxidative Stress Protein Modifications.
P2860
Q26770434-63AF9BDE-A1E2-4988-BB2B-F5B47C343068Q28083260-6BED2DE2-8B43-4F51-A57B-5A85F8BC4661Q28383441-B9EC7199-6B44-4295-B01F-58A300FC42E0Q30389594-3D788A1C-261F-4EF9-BF0B-1C520EA82B1DQ33774419-EEB8BA85-168A-4E90-AFF0-8AC7642D740BQ35120941-3D7FA6F2-AE6D-4A24-B261-1109A5753079Q35536293-AF3F37A6-BA73-4C1F-B356-0C94E9597BDCQ36122992-32A52046-5C97-4850-8D3B-93CCC1598AF2Q36124505-C5082AAC-5C50-46A1-B8D9-27E9BABBE641Q36260399-2224EA22-3ACE-48E4-97A7-807CF2993D4AQ36535395-283AED35-2939-4FE0-BA5C-C5F07C71383AQ36744820-2A2E361A-CE02-4CC7-ADAB-CACABBE7D00BQ36968079-C74AD87B-8154-4038-A1B7-475358F608C9Q37123796-30E06C9D-2AF2-4B9A-BD87-AC86E9529A1FQ38214362-6E3A0319-D968-41BC-9A51-A884B8AECCEFQ38220761-B283E2CE-4883-48DF-86B9-01A6AE5472F3Q38239205-CF8E7CDC-75F3-40D7-8ACA-EC02D6D616A4Q38261198-3BF1EC4C-8669-4503-B581-CD49E4677BBEQ38577283-1690CA1D-4D6C-4A46-8BCC-740F3A2DAD38Q38831490-3145FB13-61F0-483A-A61F-4265C95FECF0Q38835289-4771BEF9-3551-4580-9211-B18CA524C1BBQ39450537-04785A7E-29B0-4D03-88FB-B3AAB8B148ECQ42713056-51F43736-3D3F-408C-8072-829CA0BCF935Q42740912-62E3F4EB-7900-41E0-9C9E-38A494CAF867Q47305840-3E92BD1C-C1CB-40B0-9CD8-A1EB413FA76AQ47385866-FC4408A2-8973-484C-A58E-E30C81E91FF3Q47810690-021DA0CC-8AE4-4591-B3BF-212A31978F88Q48300156-13E8C4BF-8558-4C76-B127-9FC8F7098A19Q50692908-3A734BFE-EE11-4CA3-B06A-8B7AB92E2893Q52688145-FB90FD32-CC41-492E-8C30-B6EC66A34C77Q55379654-BED88F35-D1F2-4C9C-8D56-4364E08F9F00
P2860
Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Site-specific nitration of apo ...... otic plaque and dysfunctional.
@ast
Site-specific nitration of apo ...... otic plaque and dysfunctional.
@en
type
label
Site-specific nitration of apo ...... otic plaque and dysfunctional.
@ast
Site-specific nitration of apo ...... otic plaque and dysfunctional.
@en
prefLabel
Site-specific nitration of apo ...... otic plaque and dysfunctional.
@ast
Site-specific nitration of apo ...... otic plaque and dysfunctional.
@en
P2093
P2860
P356
P1476
Site-specific nitration of apo ...... otic plaque and dysfunctional.
@en
P2093
Anthony J DiDonato
Celalettin Topbas
Edward F Plow
Gary Gerstenecker
Joseph A DiDonato
Kulwant Aulak
Matthew Wagner
Paul L Fox
Ryan A Mehl
Stanley L Hazen
P2860
P304
10276-10292
P356
10.1074/JBC.M114.556506
P407
P577
2014-02-20T00:00:00Z